ORIGINAL ARTICLE   Free access

Minerva Urologica e Nefrologica 2018 February;70(1):95-101

DOI: 10.23736/S0393-2249.17.02869-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Clinical observation of umbilical cord mesenchymal stem cell transplantation for treating patients receiving peritoneal dialysis

Hong-Ying JIANG ¹, Jia-Ping WANG ², Yi-Hua BAI ¹ ✉, Min YANG ¹, Yi ZENG ¹, Yun-Juan LIAO ¹, Zhen-Kun HE ¹

¹ Department of Nephrology, the Second Hospital Affiliated Kunming Medical University, Kunming, China; ² Department of Radiology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China

BACKGROUND: This study aims to observe the outcome and safety of umbilical cord-mesenchymal stem cell (UC-MSC) treatment for continuous ambulatory peritoneal dialysis (CAPD) patients.
METHODS: A total of 24 CAPD patients, who underwent UC-MSC treatment from June 2011 to December 2012, were selected for this study. These patients were followed up until June 2015.
RESULTS: Results revealed a significant increase in hemoglobin, erythropoietin and albumin levels, a decrease in C-reactive protein levels, and marked improvement in cystatin C and urine volume within three months after UC-MSC transplantation; and the difference was statistically significant (P<0.05). However, the difference in residual glomerular filtration rate, serum creatinine, peritoneal KT/V and remnant kidney KT/V was not statistically significant (P>0.05).
CONCLUSIONS: Clinical indicators of patients with CAPD can be partially improved through UC-MSC treatment.

KEY WORDS: Umbilical cord - Mesenchymal stromal cells - Peritoneal dialysis - Therapy - C-reactive protein - Erythropoietin